Susceptibility of clinical isolates, laboratory-adapted and drug-resistant herpes simplex virus strains to helicase-primase inhibitor adibelivir (IM-250) and its synergy in combination therapy with acyclovir, penciclovir and foscarnet

ANTIVIRAL RESEARCH · Published 2026-07-30 · DOI 10.1016/j.antiviral.2026.106495

Free full text

Authors (11)

Christian Gege, Valeria Falcone, Haiying Zhu, Julia Elis, Timo Hagmaier, Bhanupriya Madarampalli, Ailyn C. Pérez-Osorio, Nathalie Pretzsch, Keith R. Jerome, Daniela Huzly, Gerald Kleymann

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Gege, C., Falcone, V., Zhu, H., et al. (2026). Susceptibility of clinical isolates, laboratory-adapted and drug-resistant herpes simplex virus strains to helicase-primase inhibitor adibelivir (IM-250) and its synergy in combination therapy with acyclovir, penciclovir and foscarnet. ANTIVIRAL RESEARCH. https://doi.org/10.1016/j.antiviral.2026.106495

Related articles

• Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage · Expert Opinion on Therapeutic Patents · 2026 · Cites or is cited by this article
• Envelope protein residue E152 confers enhanced GAS6-dependent cell entry to the African Zika virus strain MR766 · ANTIVIRAL RESEARCH · 2026 · Same journal
• Recombinant polyclonal antibody GIGA-2339 potently and pan-genotypically neutralizes hepatitis B virus · ANTIVIRAL RESEARCH · 2026 · Same journal
• Fluorescence polarization–based high-throughput screening identifies SAM-competitive inhibitors of monkeypox virus N7-methyltransferase · ANTIVIRAL RESEARCH · 2026 · Same journal
• Human monoclonal antibodies from donors vaccinated with recombinant vaccinia vaccine targeting A35 and B6 effectively inhibit orthopoxvirus spread and infection · ANTIVIRAL RESEARCH · 2026 · Same journal
• Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention · ANTIVIRAL RESEARCH · 2026 · Same journal
• A subset of histamine H4 receptor antagonists prevents B lymphocyte proliferation induced by BCR/TLR9 engagement or EBV infection · ANTIVIRAL RESEARCH · 2026 · Same journal
• A stapled viral peptide blocks HSV-2 from infecting human cervical cells · ANTIVIRAL RESEARCH · 2026 · Same journal
• Human cytomegalovirus terminase inhibitors letermovir, tomeglovir, and the halogenated benzimidazoles modify DNA cleavage/packaging to generate a super-genomic DNA species by cleavage site skipping · ANTIVIRAL RESEARCH · 2026 · Same journal
• Cell-type specific effects of SARS-CoV-2 P252L mutation on nirmatrelvir sensitivity · ANTIVIRAL RESEARCH · 2026 · Same journal